Lifestyle
- Regular weight-bearing exercise
- Adequate sun exposure for vitamin D
- Smoking cessation
Bone Gla Protein · BGP · Osteocalcin
Osteocalcin quantifies the concentration of a bone-derived hormone involved in bone formation and mineralization.
Levels vary with age and sex; higher in children and adolescents due to growth.
Osteocalcin, also known as Bone Gla Protein (BGP), is a non-collagenous protein hormone found in bone and dentin, synthesized by osteoblasts. It plays a crucial role in bone mineralization and calcium ion homeostasis. Osteocalcin is a vitamin K-dependent protein, which requires carboxylation to become biologically active. Researchers have observed that osteocalcin is involved in the regulation of bone turnover and is considered a marker of bone formation. Clinically, osteocalcin levels are used to assess bone metabolism and are particularly relevant in conditions such as osteoporosis, where bone density and strength are compromised. Elevated levels of osteocalcin may indicate increased bone turnover, which can be seen in metabolic bone diseases, hyperparathyroidism, and during periods of rapid bone growth. Conversely, reduced levels may suggest impaired bone formation or vitamin K deficiency. In the context of athletic performance and biohacking, osteocalcin has been studied for its potential role in energy metabolism and muscle function, with some evidence suggesting it may influence glucose metabolism and fat mass. However, its exact impact on athletic performance and longevity remains an area of active research. Caveats in measuring osteocalcin include its diurnal variation, with levels peaking in the early morning, and potential interference from vitamin K status. Fasting is not typically required, but consistent timing of sample collection is recommended for accurate monitoring. Factors such as age, sex, and hormonal status can also influence osteocalcin levels, necessitating careful interpretation of results in clinical practice.
Klinische Bedeutung
Elevated osteocalcin levels may indicate increased bone turnover or metabolic bone disease, while reduced levels can suggest impaired bone formation or vitamin K deficiency.
Progressively rising osteocalcin may suggest increased bone turnover or metabolic bone disease. Re-test in 3 months if levels are significantly elevated.
Falling osteocalcin levels may indicate reduced bone formation or effective treatment of high bone turnover.
Re-test Interval
3 months if outside optimal range
Note:
Consult a healthcare provider before starting new supplements, especially if on anticoagulant therapy.
Levels peak in early morning; consistent timing recommended.
Testing Frequency
Annually for those at risk of osteoporosis, more frequently if monitoring treatment response.
Correlated with
Current research suggests that the role of osteocalcin in cardiovascular risk and its relationship with vitamin K status remain unclear, particularly regarding reference ranges and optimal targets. Researchers have not yet established the mechanisms by which osteocalcin influences adolescent psychopathology, indicating a need for further exploration of its role in stress responses. Additionally, clinical questions remain unanswered about the specific thresholds of osteocalcin that predict various psychiatric disorders and the potential confounding factors influencing these associations.
581
Total Citations
14
Human/RCT
2.1
Avg. Influence
2024
Latest
Researchers found that melatonin may play a significant role in bone metabolism by promoting new bone formation and suppressing bone loss. They observed that melatonin activates specific receptors that enhance the expression of osteocalcin, a key biomarker for bone health. This study suggests that melatonin could be a novel approach for preventing and treating osteoporosis.
Mazzaferro Sandro, et al. · Seminars in nephrology · 2014
Researchers evaluated the significance of bone markers, including osteocalcin, in chronic kidney disease-mineral and bone disorders. They found that osteocalcin is involved in glucose and energy metabolism, and its activation requires vitamin K, which is often deficient in renal patients.
Key findings
Researchers explored the effects of uncarboxylated osteocalcin on glucose and lipid metabolism in KKAy mice. The study found that uncarboxylated osteocalcin significantly enhanced insulin sensitivity and improved hyperglycemia. Additionally, it was observed to alleviate hepatic steatosis and dyslipidemia in the mice.
Researchers reviewed the association of osteocalcin with cardiovascular and metabolic diseases, finding that lower circulating levels are linked to increased cardiovascular risk and insulin resistance. The study highlights the potential of osteocalcin as a biomarker for these conditions.
This research focused on developing aptamer-based assays for detecting bone density biomarkers, including osteocalcin. Researchers successfully selected high-affinity aptamers for osteocalcin, achieving a detection limit of 0.4 pg/ml. The study highlights the potential of aptasensors to improve the specificity and robustness of osteoporosis diagnostics.
Researchers found that serum osteocalcin levels were significantly associated with systemic bone mineral density loss in post-menopausal women. Changes in serum osteocalcin were also linked to loss of alveolar bone density and height. This study highlights the role of serum bone biomarkers in tracking both systemic and localized bone loss.
This meta-analysis investigated circulating levels of osteocalcin in women with gestational diabetes mellitus (GDM). Researchers found that osteocalcin levels were higher in women with GDM compared to healthy controls, although the predictive interval suggested variability. The study indicates that while osteocalcin is elevated in GDM, FABP4 may be a more suitable biomarker for identifying women at risk.
Researchers emphasized the importance of bone turnover markers like osteocalcin in pediatric medicine. They found that these markers can assist in diagnosing and monitoring bone metabolic disorders in children. This study highlights the need for further exploration of BTMs in pediatric populations.
This study investigated the correlation of Dickkopf-1 (DKK1) with multiple myeloma and its impact on osteocalcin levels. Researchers found that high DKK1 expression was associated with reduced osteocalcin deposition and shorter survival times in patients, suggesting its potential as a biomarker for prognosis.
15
Total Trials
1,969
Total Enrolled
IRCCS San Raffaele
1,000
2025
Evaluate circulating levels of osteocalcin, the main non-collagenous protein bound to hydroxyapatite (HAP) and synthesized by osteoblasts-thus considered a biomarker of bone formation-in relation to circulating vitamin D, an endocrine factor involved
Brock University
40
2024
Serum concentrations of osteocalcin
Brock University
40
2023
Osteocalcin
University of Aarhus
52
2022
Plasma concentration of Osteocalcin
Sahlgrenska University Hospital
50
2022
Change in bone turnover marker serum osteocalcin
Hospices Civils de Lyon
28
2020
Dosages of serum osteocalcin
University of Milano Bicocca
99
2020
Circulating levels of GluOC
Kennesaw State University
33
2019
Osteocalcin ng/mL
Maastricht University Medical Center
81
2011
carboxylation of osteocalcin
ETOP IBCSG Partners Foundation
119
2009
Serial serum levels of C-telopeptide, osteocalcin, and bone-specific alkaline phosphatase
BioActor
64
2008
Serum levels of Osteocalcin and CTX will be used as bone turnover markers
Duquesne University
19
2008
The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline
University College Cork
70
2008
% Undercarboxylated osteocalcin
Korean Breast Cancer Study Group
237
2007
Urinary NTX and serum osteocalcin will be assessed at baseline, 3, 6, 9, and 12 months and when unexpected skeletal related events is detected.
Pfizer
37
2005
Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on osteocalcin
Research publications about Osteocalcin over time
10totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer